Please assess the completion status of the following clinical trial:

Trial Title: Acute and Short-term Effects of CBD on Cue-induced Craving in Drug-abstinent Heroin-dependent Humans

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Must be between 21 and 65 years old~* Must have an opiate dependence that meets criteria set in the Structured Clinical Interview for Diagnostic and Statistical Manual of Mental Disorders (DSM-V) Structured Clinical Interview for DSM (SCID-V) over the last three months~* No opioid use in the past 7 days (will be verified via urine drug screen and opiate metabolite test)~Exclusion Criteria:~* Using any psychoactive drug (other than nicotine) any time up to test session 3~* Having a diagnosis of drug dependence (except for heroin or nicotine) in the past 3 months, based on the SCID-V interview criteria~* Being maintained on methadone or buprenorphine, or taking opioid antagonists such as naltrexone~* Having a positive a drug screen~* Showing signs of acute heroin withdrawal symptoms~* Having medical conditions, including Axis I psychiatric conditions under DSM-V (examined using the Mini International Neuropsychiatric Interview \[MINI\])~* Having a a history of cardiac disease, arrhythmias, head trauma, and seizures~* Having a history of hypersensitivity to cannabinoids~* Arriving to the study site visibly intoxicated as determined by a clinical evaluation for signs and symptoms of intoxication and as verified by a drug screen~* Participating in a another pharmacotherapeutic trial in the past 3 months~* Being pregnant of breastfeeding~* Not using or irregularly using appropriate methods of contraception such as hormonal contraceptives (e.g., Depo-Provera, Nuva-Ring), an intrauterine device (IUD), or double barrier method (combination of any two barrier methods used simultaneously, e.g., condoms, spermicide, diaphragms)

- Gender: ALL
- Minimum Age: 21 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Control (Type: PLACEBO_COMPARATOR): Subjects will receive a solution that resemble the Cannabidiol solution but do not have have its properties
- CBD 400mg (Type: EXPERIMENTAL): Subjects will receive 400mg of cannabidiol
- CBD 800mg (Type: EXPERIMENTAL): Subjects will receive 800 mg of cannabidiol

Based on this trial design, predict the completion outcome and termination type (if applicable).